Skip to content

Trial Summary

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.



ACTRN/NCT /ethics:


Scientific title:

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Sponsor / Cooperative group:

Eli Lilly and Company

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer Stage-
Anticipated Start Date2022-05-11
Anticipated End Date2025-05-01

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead/Kate Penta
Phone08 8359 2565
Principal InvestigatorDr Meena Okera
Recruitment StatusRecruiting